Being Diagnosed Isn't the Same as Being Studied

The ADHD treatments women are now receiving were built before anyone thought to ask how female biology affects the way they work. That oversight has a name, a mechanism, and consequences.

Special note: My book The Billion Dollar Blindspot is now available to purchase. Grab your copy and get your bonus chapter here

---

She was 56 years old when she was finally diagnosed with ADHD.

The diagnosis arrived the way late diagnoses often do. Not as a revelation but as a reckoning. Decades of compensating. Decades of systems: the lists, the alarms, the overpreparation, the private terror of forgetting something important. Decades of believing, in the way women who have never been told otherwise tend to believe, that the effort required to function was a character flaw rather than a neurological one.

The diagnosis changed that. It gave the thing a name and then came the prescription. The drug was Vyvanse—lisdexamfetamine, sold in the UK and Europe as Elvanse, the same molecule under a different name. Her doctor was attentive. The dose was standard. She filled the prescription and took the first tablet the way you take anything you have been waiting for without knowing you were waiting for it.

What happened next, she did not expect. The medication made her sleepy. Not mildly tired, but deeply, dangerously sleepy. Then one afternoon, driving home from a weekend away with friends, she fell asleep at the wheel. It was noon. She woke as she crossed the double yellow line on a two-lane highway, her car moving directly towards a truck. The truck swerved. She swerved. They were both, as she later described it, very lucky.

When she told her doctor what had happened, he said something that has stayed with her ever since:

“That side effect is an indicator you have classic ADHD.”

She had not thought to ask (and no one had told her to ask) whether the medication had been specifically studied for how it behaves in women. whether the evidence behind her prescription had asked what happens when this drug meets a hormonal environment that changes every month or whether anyone, at any point in the drug’s development, had designed a study around that question.

A few weeks ago, another reader left a comment that stopped me mid-scroll:

“Please look into Elvanse and how different sexes respond.”

That comment received eleven likes because beneath it sits a much larger question:

Once women finally receive an ADHD diagnosis, what exactly are they being handed?

The story of women and ADHD is usually told as a story of recognition. Women were missed. Women masked. Women compensated. Women were finally diagnosed.

That story is true but it stops one chapter too early.

---

Lisdexamfetamine did not arrive yesterday.

Vyvanse was introduced in the United States in July 2007 for children aged six to twelve and approved by the FDA for adults in April 2008. In the UK, NICE guidance offers lisdexamfetamine alongside methylphenidate as a first-line pharmacological option for adults with ADHD. When adult women now arrive at diagnosis — in their thirties, forties, fifties — the treatment pathway is already there. The drug, the dosing range, the prescribing guidance, and the clinical habits all exist.

This is the strange asymmetry of the moment. Women spent decades outside the diagnostic frame, and when the frame finally widened, they entered a treatment system that had already been built, already calibrated, and already closed.

The assumption, often unspoken, is that once the diagnosis is correct, the treatment question is mostly technical. Start low. Titrate. Monitor response. Adjust. But this assumes that the evidence base has already asked the questions that matter for the patient now sitting across from the clinician. In the case of women with ADHD, that assumption deserves scrutiny.

Weekly capital intelligence on women's health, delivered directly to your inbox. Summer Special - 20% off. Offer ends June 30.

The Questions The Trials Did Not Ask